Literature DB >> 32961246

Defining Endpoints and Biomarkers in Inflammatory Bowel Disease: Moving the Needle Through Clinical Trial Design.

Maria T Abreu1, William J Sandborn2.   

Abstract

Entities:  

Year:  2020        PMID： 32961246     DOI： 10.1053/j.gastro.2020.07.064

Source DB:  PubMed          Journal:  Gastroenterology        ISSN： 0016-5085            Impact factor:   22.682


× No keyword cloud information.
  2 in total

1.  Avoiding contrast-enhanced sequences does not compromise the precision of the simplified MaRIA for the assessment of non-penetrating Crohn's disease activity.

Authors:  Agnès Fernàndez-Clotet; Víctor Sapena; Nunzia Capozzi; Sonia Rodríguez; Maria-Carme Masamunt; Elena Ricart; Ingrid Ordás; Julian Panés; Jordi Rimola
Journal:  Eur Radiol       Date:  2022-01-15       Impact factor: 5.315

2.  Clinical outcomes of patients with corticosteroid refractory immune checkpoint inhibitor-induced enterocolitis treated with infliximab.

Authors:  James L Alexander; Hajir Ibraheim; Bhavisha Sheth; Jessica Little; Muhammad Saheb Khan; Camellia Richards; Nikki Hunter; Dharmisha Chauhan; Raguprakash Ratnakumaran; Kathleen McHugh; David J Pinato; Paul Nathan; Julia Choy; Shanthini M Crusz; Andrew Furness; Samra Turajlic; Lisa Pickering; James Larkin; Julian P Teare; Sophie Papa; Ally Speight; Anand Sharma; Nick Powell
Journal:  J Immunother Cancer       Date:  2021-07       Impact factor: 13.751
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.